A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin-Reference-Cited by-同舟云学术

A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin

Published:2015-12-30 Issue:2 Volume:77 Page:299-308
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Agarwal Neeraj,McPherson Jordan P.,Bailey Hanna,Gupta Sumati,Werner Theresa L.,Reddy Guru,Bhat Gajanan,Bailey Erin B.,Sharma Sunil

Funder

Topotarget

Spectrum Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2934-1.pdf

Reference33 articles.

1. Duan J, Friedman J, Nottingham L et al (2007) Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6:37–50. doi: 10.1158/1535-7163.MCT-05-0285

2. Chan D, Zheng Y, Tyner JW et al (2013) Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 139:1507–1514. doi: 10.1007/s00432-013-1465-6

3. Lin S-F, Lin J-D, Chou T-C et al (2013) Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS ONE 8:e77684. doi: 10.1371/journal.pone.0077684

4. Plumb JA, Finn PW, Williams RJ et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728

5. Sudo M, Chin TM, Mori S et al (2013) Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol 71:1325–1334. doi: 10.1007/s00280-013-2132-y

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy;Current Neuropharmacology;2024-01

2. Anticancer clinical efficiency and stochastic mechanisms of belinostat;Biomedicine & Pharmacotherapy;2023-09

3. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies;Cancer Chemotherapy and Pharmacology;2023-03

4. Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions;Toxicology Letters;2021-03

5. A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects;Clinical Pharmacology in Drug Development;2021-01-12